September 20th 2024
The approval of amivantamab plus carboplatin and pemetrexed is supported by data from the phase 3 MARIPOSA-2 trial.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Pemetrexed Injection Granted FDA Approval for Nonsquamous NSCLC and Malignant Pleural Mesothelioma
February 11th 2020The FDA has granted approval to injectable pemetrexed for the treatment of patients with locally advanced or metastatic nonsquamous non–small cell lung cancer and for those with malignant pleural mesothelioma.
Read More
Efficacy Confirmed With Osimertinib in Korean Patients With EGFR-Mutant NSCLC
February 10th 2020A subgroup analysis of Korean patients from the pooled data of two global phase II trials, AURA extension and AURA2, has found that osimertinib is as safe and effective in this subgroup of patients with pretreated EGFR-mutated advanced non-small cell lung cancer with T790M positive status as it was in the parent trials.
Read More
A Look Back at FDA News from January 2020
February 8th 2020In January 2020, the FDA approved new treatment options in gastrointestinal stromal tumors, bladder cancer, and epithelioid sarcoma. The FDA also granted several Priority Review Designations, orphan drug designations, and a Fast Track designation, as well as a Breakthrough Therapy designation.
Read More
Afatinib Monotherapy Shows Clinical Activity in Treatment-Naive EFGR-Mutant NSCLC
February 4th 2020Afatinib demonstrated clinical activity against uncommon and compound <em>EGFR</em> mutations in patients with EGFR tyrosine kinase inhibitor-naive non–small cell lung cancer, a patient population for which limited data exist on the efficacy of treatment with EGFR- tyrosine kinase inhibitors, according to Yang et al.
Read More
Addressing the Role of Consolidation Immunotherapy in Patients With Lung Cancer
February 4th 2020Nasser H. Hanna, MD, discusses the key takeaways on the current role of consolidation immunotherapy in patients with lung cancer, which has become standard in this setting. He highlights questions that still need to be addressed in this space.
Watch
Dinutuximab Plus Irinotecan Misses Overall Survival End Point in R/R SCLC
February 4th 2020The addition of the dinutuximab injection to irinotecan did not improve overall survival in patients with relapsed/refractory small cell lung cancer, failing to meet the primary end point of the phase III DISTINCT trial, according to top-line results announced in a press release from United Therapeutics, developer of dinutuximab.
Read More
Lenvatinib/Pembrolizumab Shows Promising Antitumor Activity and Safety in Select Solid Tumors
January 30th 2020In a phase II trial, the combination of lenvantinib and pembrolizumab demonstrated a manageable safety profile and encouraging antitumor activity in patients with selected advanced solid tumors. The decision to combine the agents was based on preclinical data, which suggested that VEGF and FGF signaling may enhance the therapeutic efficacy of lenvatinib.
Read More
FDA Grants Priority Review to Selpercatinib in RET Fusion+ NSCLC and Thyroid Cancer
January 29th 2020The New Drug Application for selpercatinib was granted FDA Priority Review for the treatment of patients with advanced RET fusion–positive non–small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer, based on data from the phase I/II LIBRETTO-001 trial, Eli Lilly and Company announced in a press release.
Read More
Bemcentinib Achieves Efficacy in Phase II NSCLC Trial, Setting Stage for Further Enrollment
January 21st 2020Bemcentinib in combination with pembrolizumab demonstrated clinical efficacy in the stage 1 portion of a phase II trial, which evaluated the combination in patients with non–small cell lung cancer who progressed on prior immune checkpoint inhibition, meeting the primary end point of the study.
Read More
FDA Grants Fast Track Designation to Gene Therapy Combination in EGFR-Mutant NSCLC
January 21st 2020The FDA has granted a Fast Track Designation to the immune-gene therapy Oncoprex in combination with the EGFR inhibitor osimertinib for the treatment of patients with <em>EGFR</em>-mutant non–small cell lung cancer who have progressed after treatment with osimertinib alone.
Read More
FDA Clears IND for BBT-176 in Patients with EGFR-Mutant NSCLC
January 20th 2020The Investigational New Drug Application for the novel EGFR tyrosine kinase inhibitor BBT-176 was cleared by the FDA for treatment of EGFR C797S–mutant non–small cell lung cancer, according to a press release from Bridge Biotherapeutics, Inc, developer of BBT-176.
Read More
BMI May Be a Stratification Factor for Atezolizumab in NSCLC
January 18th 2020For patients with non–small cell lung cancer, having a body mass index ≥30 at baseline could be independently associated with an improvement in overall survival with atezolizumab and could be considered a stratification factor in immune checkpoint inhibitor trials, according to a study published in JAMA Oncology.
Read More
Kirtland Discusses the American Cancer Society's Report on Significant Drop in Lung Cancer Deaths
January 18th 2020In an interview with Targeted Oncology, Steven H. Kirtland, MD, FCCP, discussed the different factors that play a role in the decline of lung cancer mortality over the last few years. He highlighted how these advancements will continue to impact the survival of patients with lung cancer and his thoughts on the evolving landscape.
Read More
Integrating a geriatric assessment into the care of older adults who are receiving cancer treatment in communi­ty oncology practices improves patient and caregiver satisfaction and encourages commu­nication about aging-related concerns, accord­ing to results of a clinical trial that enrolled 541 patients with advanced cancer.
Read More
Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers
January 18th 2020In an interview with Targeted Oncology, Pasi A. Jänne, MD, PhD, discussed the current treatment landscape for patients with EGFR-mutant lung cancer, as well as some therapies that currently are under both preclinical and clinical investigation at the Dana-Farber Cancer Institute. He shared advice for community oncologists treating this patient population.
Read More
FDA Priority Review Granted To Nivolumab/Ipilimumab for Treatment of Advanced NSCLC
January 16th 2020The FDA has granted priority review to the Biologics License Application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations, according to a press release from the Bristol-Myers Squibb Company.<br />
Read More
Telehealth Delivers Access to Care and Cutting-Edge Clinical Research to Rural Areas
January 11th 2020The present and future benefits of telehealth in oncology can be observed through Tahoe For­est Cancer Center and its affiliation with the UC Davis Cancer Center, use of other remote clinics, and participation in virtual tumor boards. Even though there are roadblocks to telehealth reaching more locations and more patients, the potential benefit warrants the time needed to get over those hurdles.
Read More
Pembrolizumab Plus Chemotherapy Phase III Study Shows Mixed Results in SCLC
January 9th 2020The combination of pembrolizumab and chemotherapy improved progression-free survival in patients with small cell lung cancer compared with chemotherapy alone, meeting 1 of the primary end points of the phase III KEYNOTE-604 study, according to a press release from pembrolizumab developer, Merck. Compared with a chemotherapy regimen of either etoposide plus cisplatin or cisplatin alone, the progression-free survival mprovement with pembrolizumab was significant.
Read More
Experts Reflect on the Most Impactful FDA Moves of 2019
January 4th 2020The FDA granted approval to countless treatments across cancer types throughout 2019 until the end of the year, with a final approval on December 31<sup>st </sup>for the first BRCA targeted therapy in pancreatic cancer. Following the excitement for a new year of further advances, Targeted Oncology followers on Twitter shared their thoughts on some of the most impactful FDA approvals in 2019.
Read More
A Look Back at FDA News from December 2019
January 2nd 2020In December 2019, the FDA approved a number of new treatments in lung cancer, pancreatic cancer, urothelial carcinoma, breast cancer, and prostate cancer. A tissue complete assay was also approved by the FDA for use in a clinical trial evaluating pembrolizumab.
Read More
Osimertinib Shows Antitumor Activity in NSCLC Harboring Uncommon EGFR Mutations
December 31st 2019Osimertinib demonstrated a manageable toxicity profile and encouraging activity in patients with non–small cell lung cancer who harbor an uncommon EGFR mutation, according to results from a phase II clinical trial conducted in Korea.
Read More
First Randomized Phase III Trial Opens for Treatment-Naive RET Fusion-Positive NSCLC
December 28th 2019Selpercatinib will be compared with the standard of care in the first ever phase III clinical trial in patients with advanced or metastatic treatment-naïve <em>RET</em> fusion-positive non–small cell lung cancer, according to a press release from Eli Lilly and Company.
Read More
Regulatory Approval Moves Ahead for Lurbinectedin in SCLC
December 19th 2019A new drug application has been filed for accelerated approval with the FDA for lurbinectedin in patients with small cell lung cancer who have progressed after prior platinum-containing therapy, according to the manufacturer, PharmaMar.1 The filing was based on results from a phase II basket trial, presented at the 2019 ASCO Annual Meeting.
Read More
Pembrolizumab Boosts Survival in Metastatic Nonsquamous NSCLC Regardless of KRAS Mutations
December 16th 2019Pembrolizumab showed improvements in overall survival, progression-free survival, and objective response rate compared with pemetrexed or paclitaxel chemotherapy in patients with metastatic nonsquamous non–small cell lung cancer whose tumors are PD-L1–positive, regardless of their KRAS mutational status.
Read More
EGFR TKI Resistance Identified in a Patient with EGFR- and BRAF-Mutant Lung Adenocarcinoma
December 14th 2019In an interview with Targeted Oncology, Brennan J. Decker, MD, PhD, discussed a real-life scenario of a patient with lung cancer who harbored both an EGFR and BRAF mutation. He highlighted the key takeaways of this case, which he presented at the 2019 Association for Molecular Pathology Annual Meeting and Expo.
Read More
Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC
December 13th 2019With the inevitability of resistance to first- and second-generation EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non–small cell lung cancer, novel options like lazertinib, an irreversible, third-generation, mutant-selective, EGFR TKI are being explored. Lazertinib has shown promise for the treatment of this patient population, according to a phase I/II dose-escalation study published in The Lancet Oncology.
Read More
Pennell Treats a Patient With NSCLC and a Genetic Mutation
December 13th 2019In a Targeted Oncology case-based peer perspectives live discussion, Nathan A. Pennell, MD, PhD, associate professor of the Department of Medicine at Case Western Reserve University and a medical oncologist at Taussig Cancer Center and the Cleveland Clinic Cancer Center discussed treatment options for EGFR-mutant non–small cell lung cancer, based on the case of a real patient.<br />
Read More